NCT04066322

Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment

Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment: Real World Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 180 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the efficacy and tolerability of surgery in selecting patients who can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis after induction systemic treatment. The willing of participants decide who receive surgery and who will continue to receive standard systemic treatment.

Detailed description

system treatments of metastatic PanNET include SSA, sunitinib, mTOR inhibitor and chemotherapy. For patients achieved PR/SD after system treatment, resection of primary tumor and metastasis maybe a better way to decline tumor burden and get longer survival. this real world study is focused on this group of patients with metastatic PanNET, and to evaluate the efficacy and tolerability of surgery in selecting patients who can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis after induction systemic treatment.

Conditions

• Neuroendocrine Tumors
• Metastases
• Surgery

Interventions

Type	Name	Description
PROCEDURE	system treatment and surgery	to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.
OTHER	system treatment	to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.

Timeline

• Start date: 2019-08-25
• Primary completion: 2024-07-25
• Completion: 2025-07-25
• First posted: 2019-08-26
• Last updated: 2019-09-24

Locations

1 site across 1 country: China